FAT1 loss-of-function mutations have been associated with drug resistance in patients with ER+ breast cancer treated with CDK 4/6 inhibitors via a mechanism involving the Hippo pathway and changes in gene expression caused by YAP129. This evidence concerns the gene FAT1 and breast cancer.